BNET Industries
Market Cap:$150.1B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Barclays appoints US lev loan syndicate head - memo
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
News & Analysis
Filter by
company and pfizer inc. and pharmaceutical company - All News and Analysis
Pfizer-Pharmacia fallout could be Rx for small firms.(laid-off scientists could fill slots at smaller new companies)(Brief Article)
- 2002-07-29
Historically, mergers of big pharmaceutical companies in Michigan have given life to small biotechnology companies when disgruntled or laid-off scientists left. Experts say Pfizer Inc.'s acquisition of Pharmacia Corp. is likely no exception. The h Historically, mergers of big pharmaceutical companies in Michigan...
Pharma's Consolidation Creates New Kind of Player.(Statistical Data Included)
- 2000-05-29
Companies become broader and more efficient. THE RECENT merger and acquisition activity in the drug industry is changing the landscape of pharmaceutical players. Within just the past two years, consolidation has created a new breed of super dr Companies...
Battle Over Warner-Lambert Could Fuel Consolidations.
- 1999-11-29
European firms may be at a disadvantage in R&D spending. THE TAKEOVER BATTLE between Pfizer Inc. and Warner-Lambert Company is forcing European drug manufacturers to reevaluate their positions in the global pharmaceutical industry. Analyst European firms may be at...
Drug Producers Continue To Record Strong Results.
- 1999-10-25
W-L and Pfizer lead with strong sales and earnings. THE LARGEST US drug manufacturers are posting third quarter earnings growth in the mid-teens and higher, just as analysts predicted. The industry's leaders include Warner-Lambert Company and W-L and...
CHANGING CLIMATE: UNCERTAINTY COOLS INTEREST IN DRUG COMPANY STOCKS; POLITICS, LACK OF NEW MEDICINES HAS SOME WARY.
- 1999-03-08
Meddling by President Clinton and a lack of blockbuster drugs in the pipeline raise red flags for institutional managers investing in the drug industry. Large-cap pharmaceutical companies such as Pfizer Inc. and Merck & Co. Inc. have been popu Meddling by President Clinton...
Pharma earnings surge on healthy drug sales. (Merck and Company Inc., Pfizer Inc. and Johnson and Johnson first quarter 1997 financial results)
- 1997-05-05
The pharmaceutical industry enjoyed a robust first fiscal quarter, with many companies netting double-digit earnings gains. New product sales and new categories of medications exploded while some veteran drugs also turned in strong performances. The pharmaceutical industry enjoyed a robust first...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
